SPARCL1 suppresses metastasis in prostate cancer
Authors:
- Yuzhu XiangYXYuzhu Xiang
- Qingchao QiuQQQingchao Qiu
- Ming JiangMJMing Jiang
- Renjie JinRJRenjie Jin
- Brian D. LehmannBLBrian D. Lehmann
- Douglas W. StrandDSDouglas W. Strand
- Bojana JovanovicBJBojana Jovanovic
- David J. DeGraffDDDavid J. DeGraff
- Yi ZhengYZYi Zheng
- Dina A. YousifDYDina A. Yousif
- Christine Q. SimmonsCSChristine Q. Simmons
- Thomas C. CaseTCThomas C. Case
Open Access
- 20 July 2013
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 7 (6) , 1019-1030
Abstract
Purpose: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level.Experimental design: Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo.Results: SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models.Conclusions: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.Keywords
Funding Information
- National Cancer Institute at the National Institutes of Health (CA114033)
- American Cancer Society-Institutional Research (IRG-58-009-51, IRG-58-009-53)
- National Center for Research Resources (NCRR) (UL1 RR024975)
- National Institutes of Health (NIH) (CRC1838)
- National Cancer Institute (4R01-CA076142-14 to RJM)
- American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship
This publication has 50 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomeProceedings of the National Academy of Sciences, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- β2-Microglobulin Induces Epithelial to Mesenchymal Transition and Confers Cancer Lethality and Bone Metastasis in Human Cancer CellsCancer Research, 2011
- Preclinical Mouse Models of Human Prostate Cancer and Their Utility in Drug DiscoveryCurrent Protocols in Pharmacology, 2010
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Web-based interrogation of gene expression signatures using EXALTBMC Bioinformatics, 2009
- Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell lineProceedings of the National Academy of Sciences, 2008
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Delineation of prognostic biomarkers in prostate cancerNature, 2001